Method and compositions for treating viral infection
Inventors
Newman, Robert A. • ADDINGTON, Otis C.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11123387-B2
Publication Date
2021-09-21
Expiration Date
Abstract
A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae family, Flaviviridae family (Flavivirus genus), Deltaretrovirus genus, or Togaviriade family is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene. Alternatively, the composition comprises at least one, at least two, or at least three triterpenes.
Core Innovation
The disclosure relates to antiviral pharmaceutical compositions that comprise one or more cardiac glycosides, including digoxin and oleandrin, for treating viral infections. The compositions are described as digoxin-containing and are associated with defined plasma concentrations of digoxin in a subject following administration.
The disclosed use targets viral infections caused by Filovirus, Ebolavirus or Marburgvirus, and is described in the context of treating infections across multiple viral families, including Flaviviridae and Togaviridae. Administration can be immediate after infection or within one day to 5 days after infection, or at the earliest time after definite diagnosis.
A prophylactic approach is also described for treating a subject at risk of contracting Filovirus-, Ebolavirus- or Marburgvirus-caused infection. The prophylactic method is described as chronically administering therapeutically effective doses of the digoxin-containing antiviral composition on a recurring basis over an extended treatment period prior to the subject contracting the viral infection.
Claims Coverage
The independent claims cover two method categories: therapeutic treatment of Filovirus/Ebolavirus/Marburgvirus infection and prophylactic treatment of a subject at risk of contracting such infection. The claim set uses a defined digoxin plasma concentration requirement of about 0.05 to about 2.5 ng/mL and includes timing, dosing modality, and prophylactic versus therapeutic intent.
Digoxin antiviral composition for treating Filovirus, Ebolavirus or Marburgvirus infection with defined plasma concentration and treatment window
A method of treating a viral infection caused by Filovirus, Ebolavirus or Marburgvirus in a subject in need thereof, comprising administering one or more therapeutically effective doses of an antiviral composition comprising digoxin, wherein following administration the plasma concentration of digoxin is in the range of about 0.05 to about 2.5 ng/mL, and wherein the antiviral composition is administered immediately after infection or any time within one day to 5 days after infection or at the earliest time after definite diagnosis.
Chronic prophylactic digoxin administration with defined plasma concentration to prevent contracting Filovirus, Ebolavirus or Marburgvirus infection
A prophylactic method of treating a subject at risk of contracting a viral infection caused by Filovirus, Ebolavirus or Marburgvirus, comprising chronically administering one or more therapeutically effective doses of an antiviral composition comprising digoxin on a recurring basis over an extended treatment period prior to the subject contracting the viral infection, thereby preventing the subject from contracting the viral infection; wherein following administration the plasma concentration of digoxin is in the range of about 0.05 to about 2.5 ng/mL.
Across the independent claims, the principal claim architecture centers on administering a digoxin-containing antiviral composition with a specified post-administration plasma digoxin concentration range. The therapeutic independent claim limits the administration timing to immediate-to-1–5 days after infection, while the prophylactic independent claim requires chronic, recurring administration prior to infection to prevent contracting the infection.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?